{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:31:13Z","timestamp":1790613073533,"version":"4.1.0"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","award":["21-CID-04"],"award-info":[{"award-number":["21-CID-04"]}],"id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2022,4,20]]},"abstract":"\n Rezafungin is a new echinocandin under development for the treatment of candidemia and invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and epidemiological cutoff values for\n Candida<\/jats:italic>\n spp. and rezafungin. The activities of rezafungin and comparators against 2019 to 2020 invasive fungal isolates was evaluated by applying the new CLSI breakpoints. Rezafungin demonstrated potent activity against\n Candida albicans<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.03\/0.06\u2009mg\/L; 100.0% susceptible),\n Candida tropicalis<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.03\/0.06\u2009mg\/L; 100% susceptible),\n Candida glabrata<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.06\/0.06\u2009mg\/L; 98.3% susceptible),\n Candida krusei<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.03\/0.03\u2009mg\/L; 100% susceptible), and\n Candida dubliniensis<\/jats:named-content>\n (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 0.06\/0.12\u2009mg\/L; 100% susceptible) when tested by the CLSI broth microdilution method. Rezafungin inhibited 99.6% of\n Candida parapsilosis<\/jats:named-content>\n isolates (MIC\n 50<\/jats:sub>\n \/MIC\n 90<\/jats:sub>\n , 1\/2\u2009mg\/L) at the susceptible breakpoint of \u22642\u2009mg\/L. All\n C. albicans<\/jats:named-content>\n ,\n C. tropicalis<\/jats:named-content>\n , and\n C. krusei<\/jats:named-content>\n isolates, as well as most\n C. glabrata<\/jats:named-content>\n (96.2% to 97.9%) and\n C. parapsilosis<\/jats:named-content>\n (86.2% to 100%) isolates, were susceptible to comparator echinocandins. Fluconazole resistance was detected among 0.5%, 4.5%, 10.5%, and 1.2% of\n C. albicans<\/jats:named-content>\n ,\n C. glabrata<\/jats:named-content>\n ,\n C. parapsilosis<\/jats:named-content>\n , and\n C. tropicalis<\/jats:named-content>\n isolates, respectively. All echinocandins displayed limited activity against\n Cryptococcus neoformans<\/jats:named-content>\n . Rezafungin and other echinocandins were active against\n Aspergillus fumigatus<\/jats:named-content>\n (minimum effective concentration for 90% of isolates tested [MEC\n 90<\/jats:sub>\n ] range, 0.015 to 0.06\u2009mg\/L) and\n Aspergillus<\/jats:named-content>\n section\n Flavi<\/jats:italic>\n (MEC\n 90<\/jats:sub>\n range, 0.015 to 0.03\u2009mg\/L). All but 16 (8.6%)\n A. fumigatus<\/jats:named-content>\n isolates were susceptible to voriconazole, and 100% of\n Aspergillus<\/jats:named-content>\n section\n Flavi<\/jats:italic>\n isolates were WT to mold-active azoles. When applying the CLSI clinical breakpoints, rezafungin displayed high susceptibility rates (>98.0%) against\n Candida<\/jats:italic>\n isolates from invasive fungal infections and showed potent activity against\n Aspergillus<\/jats:named-content>\n isolates.\n <\/jats:p>","DOI":"10.1128\/jcm.02449-21","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T04:30:16Z","timestamp":1646627416000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":35,"title":["Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)"],"prefix":"10.1128","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-3754","authenticated-orcid":true,"given":"Cecilia G.","family":"Carvalhaes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-8286","authenticated-orcid":true,"given":"Abby L.","family":"Klauer","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6798-7653","authenticated-orcid":true,"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-6068","authenticated-orcid":true,"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy358"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115473"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01811-20"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6040262"},{"key":"e_1_3_2_8_2","unstructured":"CLSI. 2021. Subcommittee (SC) on Antifungal Susceptibility Tests. June 2021 meeting minutes. Available at: https:\/\/clsi.org\/media\/gvuivvig\/2021_summer_afsc_agenda_summary_minutes.pdf."},{"key":"e_1_3_2_9_2","unstructured":"CLSI. 2021. Subcommittee (SC) on Antifungal Susceptibility Tests. June 2021 meeting files. https:\/\/clsi.org\/meetings\/sub-antifungal\/antifungal-susceptibility-testing-files-resources\/."},{"key":"e_1_3_2_10_2","volume-title":"M59Ed3. Epidemiological cutoff values for antifungal susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. M59Ed3. Epidemiological cutoff values for antifungal susceptibility testing, third edition. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-012-9551-x"},{"key":"e_1_3_2_12_2","volume-title":"MM18Ed2E. Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing.","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. MM18Ed2E. Interpretive criteria for identification of bacteria and fungi by targeted DNA sequencing. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01902-12"},{"key":"e_1_3_2_14_2","volume-title":"M27Ed4. Reference method for broth dilution antifungal susceptbility testing of yeasts.","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. M27Ed4. Reference method for broth dilution antifungal susceptbility testing of yeasts. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","volume-title":"M38Ed3. Reference method for broth dilution antifungal susceptibilty testing of filamentous fungi","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. M38Ed3. Reference method for broth dilution antifungal susceptibilty testing of filamentous fungi, third edition. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_16_2","volume-title":"M60Ed2. Performance standards for antifungal susceptibility testing of yeasts.","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. M60Ed2. Performance standards for antifungal susceptibility testing of yeasts. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_17_2","volume-title":"M61Ed2 Performance standards for antifungal susceptibility testing of filamentous fungi","author":"Clinical and Laboratory Standards Institute","year":"2020","unstructured":"Clinical and Laboratory Standards Institute. 2020. M61Ed2 Performance standards for antifungal susceptibility testing of filamentous fungi, second edition. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00906-17"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab336"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10408410903241444"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2018.02.013"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc10514"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa016"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00701-16"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01627-16"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00758-17"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01390-21"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00842-21"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01556-19"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02154-17"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_3_2_32_2","volume-title":"M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement.","author":"Clinical and Laboratory Standards Institute","year":"2021","unstructured":"Clinical and Laboratory Standards Institute. 2021. M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-20"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2015.08.001"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy859"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.02449-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.02449-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T09:02:37Z","timestamp":1650445357000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.02449-21"}},"subtitle":[],"editor":[{"given":"Kimberly E.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,20]]}},"alternative-id":["10.1128\/jcm.02449-21"],"URL":"https:\/\/doi.org\/10.1128\/jcm.02449-21","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"2021-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02449-21"}}